Amber Zavala

Amber Zavala serves as the primary contracting officer for Nac Pharmaceuticals under the Department of Veterans Affairs, overseeing the procurement of critical pharmaceutical products essential to veteran healthcare delivery. In this role, she manages the full lifecycle of acquisition activities—from market research and solicitation to contract award and administration—ensuring timely access to high-demand prescription medications, including chronic disease therapies and acute care treatments. Her work directly supports the VA’s mission to maintain a secure, uninterrupted pharmaceutical supply chain for enrolled veterans nationwide, with a focus on compliance, regulatory alignment, and operational efficiency in federal pharmaceutical procurement. Zavala maintains consistent working relationships with leading pharmaceutical manufacturers and distributors, including Avkare LLC, Progenics Pharmaceuticals Inc., Dr. Reddy’s Laboratories, Golden State Medical Supply, and Seqirus USA Inc. These partnerships reflect a preference for established industry players with proven capabilities in GMP-compliant manufacturing, cold-chain logistics, and FDA-regulated drug distribution. Her contracting approach emphasizes reliability, regulatory adherence, and supply chain resilience, prioritizing vendors with demonstrated capacity to meet VA’s stringent quality and delivery standards. Zavala’s procurement portfolio reflects a 100% non-set-aside orientation, with no utilization of 8(a), HUBZone, SDVOSB, or other socioeconomic set-asides. This reflects a strategic focus on securing the broadest possible supplier base from established pharmaceutical manufacturers capable of meeting large-scale, mission-critical demand without restriction, ensuring maximum competition among qualified entities with the necessary regulatory and production infrastructure. Her primary procurement activity centers on NAICS 325412—Pharmaceutical Preparation Manufacturing—encompassing the acquisition of finished dosage forms, including tablets, injectables, and controlled substances. She possesses deep expertise in pharmaceutical supply chain dynamics, regulatory compliance under 21 CFR Part 211, and the unique logistical demands of federal pharmaceutical distribution, making her a key steward of VA’s pharmaceutical acquisition ecosystem.